Abstract
Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins. Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis. Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 1217-1221 |
| Number of pages | 5 |
| Journal | Annals of Oncology |
| Volume | 21 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Nov 2 2009 |
Fingerprint
Keywords
- Diffuse large B-cell lymphoma
- Rituximab
- Statin
ASJC Scopus subject areas
- Oncology
- Hematology
- Medicine(all)
Cite this
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. / Ennishi, Daisuke; Asai, H.; Maeda, Yoshinobu; Shinagawa, K.; Ikeda, K.; Yokoyama, M.; Terui, Y.; Takeuchi, K.; Yoshino, Tadashi; Matsuo, K.; Hatake, K.; Tanimoto, M.
In: Annals of Oncology, Vol. 21, No. 6, 02.11.2009, p. 1217-1221.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
AU - Ennishi, Daisuke
AU - Asai, H.
AU - Maeda, Yoshinobu
AU - Shinagawa, K.
AU - Ikeda, K.
AU - Yokoyama, M.
AU - Terui, Y.
AU - Takeuchi, K.
AU - Yoshino, Tadashi
AU - Matsuo, K.
AU - Hatake, K.
AU - Tanimoto, M.
PY - 2009/11/2
Y1 - 2009/11/2
N2 - Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins. Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis. Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.
AB - Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins. Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis. Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.
KW - Diffuse large B-cell lymphoma
KW - Rituximab
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=77954024437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954024437&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdp490
DO - 10.1093/annonc/mdp490
M3 - Article
VL - 21
SP - 1217
EP - 1221
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 6
ER -